J&J job cuts hit Belgian subsidiary

Johnson & Johnson's restructuring has come home to roost in Belgium. Drug maker Janssen-Cilag, a J&J subsidiary, will slice 521 full-time and 167 part-time workers from its payroll of 4,723 in-country.

Back in July, J&J announced it would cut its global work force by up to 4,820 jobs. Contributing factors: Falling stent sales, lagging Procrit prescriptions, and expiring patents. It's the company's biggest cutback ever, amounting to about 4 percent of its payroll. An update on the restructuring is due with third-quarter earnings reports October 16.

- check out the article in the International Herald Tribune

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.